切伦科夫发光成像:一种快速且相关的临床前肿瘤缺氧评估工具
本研究在小鼠结肠癌模型中,比较了18F-FMISO PET、BOLD-MRI与切伦科夫发光成像(CLI)检测肿瘤缺氧的能力。结果显示FMISO PET与CLI肿瘤摄取显著相关,CLI的肿瘤-本底比显著高于PET和MRI,且CLI工作流程比PET-MRI快约八倍,表明CLI是评估肿瘤缺氧的快速有效工具。
要点
- FMISO PET与CLI肿瘤摄取显著相关,免疫组化确认肿瘤缺氧。
- CLI肿瘤-本底比显著高于PET和MRI。
- CLI工作流程比PET-MRI快约八倍,适合高通量药物开发。
核心结论
- CLI是评估肿瘤缺氧的快速且相关工具,尤其适合缺氧靶向药物开发。
研究设计与样本
- 小鼠皮下注射1×10^6个CT-26细胞诱导结肠癌模型,注射FMISO后行同步PET-BOLD-MRI及CLI,并行哌莫硝唑免疫组化染色。
主要发现
- FMISO PET与CLI肿瘤摄取显著相关,与BOLD-MRI映射一致。
- CLI的肿瘤-本底比显著高于PET和MRI。
- 免疫组化确认肿瘤缺氧。
- CLI工作流程比PET-MRI流程快约八倍。
临床怎么用
- CLI可用于临床前肿瘤缺氧的快速评估,支持缺氧靶向药物开发中的高通量筛选。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Molecular imaging techniques visualise biomarkers for both drug development and personalised medicine. In this field, Cherenkov luminescence imaging (CLI) seems to be very attractive by allowing imaging with clinical PET radiotracers with high-throughput capabilities. In this context, we developed a fast CLI method to detect tumour hypoxia with 18F-fluoromisonidazole (FMISO) for drug development purposes. METHODS: Colon cancer model was induced in mice by subcutaneous injection of 1 × 106 CT-26 cells. FMISO was injected, and simultaneous PET-blood oxygen level dependent (BOLD)-MRI followed by CLI were performed along with immunohistochemistry staining with pimonidazole. RESULTS: There was a significant correlation between FMISO PET and CLI tumour uptakes, consistent with the BOLD-MRI mapping. Tumour-to-background ratio was significantly higher for CLI compared with PET and MRI. Immunohistochemistry confirmed tumour hypoxia. The imaging workflow with CLI was about eight times faster than the PET-MRI procedure. CONCLUSION: CLI is a fast and relevant tool to assess tumour hypoxia. This approach could be particularly interesting for hypoxia-targeting drug development.
引用
- Desvaux E, Courteau A, Bellaye PS, et al. Cherenkov luminescence imaging is a fast and relevant preclinical tool to assess tumour hypoxia in vivo. EJNMMI Res. 2018. PMID: 30574662. doi:10.1186/s13550-018-0464-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。